Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently, the anti-tumor activity of
N-myc downstream-regulated gene 2
(
NDRG2
) was elucidated, but the molecular mechanism of how
NDRG2
works as a tumor suppressor is not well known. To determine the function of
NDRG2
as a tumor suppressor, we established stable cell lines expressing NDRG2 protein or its mutant forms, and studied their effects on tumor cell growth. Interestingly, constitutive expression of wild-type
NDRG2
induced the growth retardation of SW620 colon carcinoma cells. Introduction of
NDRG2
into SW620 cells induced the decrease of c-Jun phosphorylation at Ser63, followed by the attenuation of activator protein-1 (AP-1) function as a
transcriptional activator
. Subsequently, the down-regulation of cyclin D1, which is known as a major target for AP-1 transcription activator, resulted in cell cycle arrest at G1/S phase. Additionally, treatment of
NDRG2
-siRNA on
NDRG2
-expressing cells has induced the recovery of c-Jun phosphorylation and cyclin D1 expression. Cell proliferation of those cells was also increased compared with untreated cells.
NDRG2
mutants of which the phosphorylation sites at C-terminal region were removed by deletion or site-directed mutagenesis have shown no effect on cyclin D1 expression and could not induce cell growth retardation. In conclusion,
NDRG2
modulates intracellular signals to control cell cycle through the regulation of cyclin D1 expression via phosphorylation pathway.
...
PMID:NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. 1884 21